FDA Suspends Ixchiq Chikungunya Vaccine Due to Safety Concerns
On August 22, 2025, the U.S. Food and Drug Administration (FDA) announced the suspension of the biologics license for the chikungunya vaccine Ixchiq, developed by Valneva Austria GmbH. This decision…